| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
I-Mab (NASDAQ:IMAB) (the Company), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer, today announced that an abstract related to updated data from the Phase 1 study of givastomig as a monotherapy in heavily pre-treated patients with gastroesophageal carcinoma (GEC) has been accepted as a "short-talk" at the AACR-NCI-EORTC conference which will be held October 22-26 in Boston, Massachusetts.
"As we follow patients in the fully enrolled givastomig Phase 1b dose expansion study and advance the program towards the initiation of a randomized Phase 2 study in gastric cancers, we appreciate the opportunity to present additional Phase 1 data demonstrating givastomig's monotherapy activity and engage with the oncology community. These data support our Phase 2 strategy to combine givastomig with standard of care in first line GEC patients with a broad range of Claudin 18.2 expression levels," said Phillip Dennis, MD, PhD, Chief Medical Officer of I-Mab.
AACR-NCI-EORTC Conference Information:
Title: Updated Safety, Efficacy and Biomarker Analysis from the Phase I Study of Givastomig, a Novel Claudin 18.2/4-1BB Bispecific Antibody, in Claudin 18.2 Positive Advanced Gastroesophageal Carcinoma (GEC)
Session: Concurrent Session 2: Bispecifics/T-cell Engagers
Speaker: Samuel J. Klempner, MD, Associate Professor of Medicine, Massachusetts General Hospital
Presentation Number: B016
Date and Time: Thursday, October 23, 6:20 – 6:35 PM ET
Location: Hynes Convention Center
Posted In: IMAB
